Top Markets
Coin of the day
Australian Clinical Labs Limited Australian Clinical Labs Limited

Australian Clinical Labs Limited

ACL
Clasificación en acciones #15163
Australian Clinical Labs Limited operates across Australia, delivering a... Australian Clinical Labs Limited operates across Australia, delivering a diverse range of diagnostic pathology services. The company's extensive portfolio encompasses standard examinations alongside advanced molecular genetics, including Harmony NIPT and initial trimester screenings, as well as genetic carrier screening. Furthermore, it provides detailed analyses in chemical, tissue (histopathology), and cellular (cytopathology) pathology; specialized tests for hematology, allergies, and immunology; and comprehensive serology and microbiology services. ACL also performs infectious molecular testing, cardiac diagnostic assessments, functional pathology, veterinary pathology, and commercial drug and alcohol screening. These essential services are supplied to both private and public hospitals throughout the nation. The company was founded in 2020 and maintains its primary operational base in Clayton, Australia.
Precio por acción
$1.98
Capitalización bursátil
$368.99M
Cambio (1 día)
0.90%
Cambio (1 año)
11.38%
País
AU
Comercio Australian Clinical Labs Limited (ACL)

Categoría

Ingresos de Australian Clinical Labs Limited (ACL)
Ingresos en Sep 2026 TTM: 0
Según los últimos informes financieros de Australian Clinical Labs Limited, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Australian Clinical Labs Limited desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
$46.34B -
US
$25.11B -
US
- -
CN
$2.71B -
US
$4.55B -
US